- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00760877
Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)
An Open Label, Randomized Study of Nilotinib vs. Standard Imatinib (400/600 mg QD) Comparing the Kinetics of Complete Molecular Response for CML-CP Patients With Evidence of Persistent Leukemia by RQ-PCR.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
Buenos Aires
-
Caba, Buenos Aires, Argentina, C1221ADH
- Novartis Investigative Site
-
-
-
-
New South Wales
-
St. Leonards, New South Wales, Australia, 2065
- Novartis Investigative Site
-
Westmead, New South Wales, Australia, 2145
- Novartis Investigative Site
-
-
Queensland
-
Herston, Queensland, Australia, 4029
- Novartis Investigative Site
-
South Brisbane, Queensland, Australia, 4101
- Novartis Investigative Site
-
Woolloongabba, Queensland, Australia, 4102
- Novartis Investigative Site
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Novartis Investigative Site
-
-
Victoria
-
Parkville, Victoria, Australia, 3050
- Novartis Investigative Site
-
Prahran, Victoria, Australia, 3181
- Novartis Investigative Site
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6009
- Novartis Investigative Site
-
-
-
-
MG
-
Belo Horizonte, MG, Brasile, 30130-100
- Novartis Investigative Site
-
-
PR
-
Curitiba, PR, Brasile, 80060-900
- Novartis Investigative Site
-
-
RJ
-
Rio de Janeiro, RJ, Brasile, 21941-913
- Novartis Investigative Site
-
-
SP
-
Campinas, SP, Brasile, 13083-970
- Novartis Investigative Site
-
Sao Paulo, SP, Brasile, 05403-000
- Novartis Investigative Site
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 1M9
- Novartis Investigative Site
-
-
Ontario
-
Hamilton, Ontario, Canada, L8H 4J9
- Novartis Investigative Site
-
Toronto, Ontario, Canada, M5G 2M9
- Novartis Investigative Site
-
-
Quebec
-
Montreal, Quebec, Canada, H1T 2M4
- Novartis Investigative Site
-
Québec, Quebec, Canada, G1J 1Z4
- Novartis Investigative Site
-
-
-
-
-
Bordeaux, Francia, 33076
- Novartis Investigative Site
-
Creteil, Francia, 94010
- Novartis Investigative Site
-
Lyon cedex 04, Francia, 69317
- Novartis Investigative Site
-
Paris, Francia, 75010
- Novartis Investigative Site
-
Vandoeuvre les Nancy, Francia, 54511
- Novartis Investigative Site
-
-
-
-
-
Madrid, Spagna, 28006
- Novartis Investigative Site
-
Madrid, Spagna, 28007
- Novartis Investigative Site
-
-
Andalucia
-
Malaga, Andalucia, Spagna, 29010
- Novartis Investigative Site
-
-
Cataluña
-
Barcelona, Cataluña, Spagna, 08036
- Novartis Investigative Site
-
-
Navarra
-
Pamplona, Navarra, Spagna, 31008
- Novartis Investigative Site
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
Diagnosis of chronic myeloid leukemia associated with BCR-ABL quantifiable by RQ-PCR Documented CCyR by bone marrow or BCR-ABL<1% IS in the past 12 months Persistent disease demonstrated by two PCR positive tests 3 months apart both during the past 6 months.
Treatment with imatinib for at least 2 years with 400 mg or 600 mg and a stable dose No other current or planned anti-leukemia therapies
Exclusion Criteria:
Patient has evidence of rising PCR (a confirmed >1 log increase in previous 6 months) Patient has received another investigational agent within last 6 months or tyrosine kinase inhibitors (TKIs) other than imatinib Prior allogeneic stem cell transplantation
Impaired cardiac function including any one of the following:
Inability to monitor the QT interval on electrocardiogram (ECG) Long QT syndrome or a known family history of long QT syndrome. Clinically significant resting brachycardia (<50 beats per minute) QTc > 450 msec on baseline ECG (using the QTcF formula). If QTcF >450 msec and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for QTc Myocardial infarction within 12 months prior to starting study Other clinically significant uncontrolled heart disease (e.g. unstable angina, congestive heart failure or uncontrolled hypertension) History of or presence of clinically significant ventricular or atrial tachyarrhythmias Administration of cytokine therapy (e.g. G-CSF, GM-CSF or SCF) within 4 weeks prior to study entry
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Nilotinib
Participants received Nilotinib 400 mg orally twice daily (bid) for 48 months.
|
Supplied in 200 mg capsules
|
Comparatore attivo: Imatinib
Participants received Imatinib 400 mg or 600 mg once daily (qd) (based on the participant's dose prior to randomization) for 48 months.
|
Supplied in 100 mg and 400 mg capsules
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Rate of Confirmed Best Cumulative Complete Molecular Response (CMR)
Lasso di tempo: 12 months
|
The rate of confirmed best cumulative CMR was defined as the number of participants who had confirmed CMR during the first 12 months of treatment after the randomization date.
Participants who achieved confirmed best cumulative CMR during the first 12 months were considered responders.
Participants who dropped out early or who did not provide sufficient data for any reason were considered to be non-responders.
The definition of CMR is undetectable BCR-ABL (fusion gene formed between bcr gene from chromosome 22 and abl gene from chromosome 9) where BCR-ABL ratio in % international scale (IS) ≤ 0.00001 by real-time quantitative polymerase chain reaction (RQ-PCR) where there was no detectable BCR-ABL and 1) the test had a sensitivity of at least 4.5 logs below the standardized baseline; 2) RQ-PCR negativity was confirmed on the next RQ-PCR sample (usually 3 months later); and 3) the date of confirmed CMR was the date of the first of two negative results with sensitivity >4.5 logs.
|
12 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Rate of Confirmed Best Cumulative CMR
Lasso di tempo: 24 months, 36 month, 48 months
|
The rate of confirmed best cumulative CMR was defined as the number of participants who had confirmed CMR during the 24, 36 and 48 months post treatment after the randomization date.
Participants who achieved confirmed best cumulative CMR during the first 12 months were considered responders.
Participants who dropped out early or who did not provide sufficient data for any reason were considered to be non-responders.
The definition of CMR is undetectable BCR-ABL (fusion gene formed between bcr gene from chromosome 22 and abl gene from chromosome 9) where BCR-ABL ratio in % international scale (IS) ≤ 0.00001 by RQ-PCR where there was no detectable BCR-ABL and 1) the test had a sensitivity of at least 4.5 logs below the standardized baseline; 2) RQ-PCR negativity was confirmed on the next RQ-PCR sample (usually 3 months later); and 3) the date of confirmed CMR was the date of the first of two negative results with sensitivity >4.5 logs.
|
24 months, 36 month, 48 months
|
Number of Cross-over Participants With CMR
Lasso di tempo: 24 months, 36 months, 48 months
|
The definition of CMR is undetectable BCR-ABL (fusion gene formed between bcr gene from chromosome 22 and abl gene from chromosome 9) where BCR-ABL ratio in % international scale (IS) ≤ 0.00001 by RQ-PCR where there was no detectable BCR-ABL and 1) the test had a sensitivity of at least 4.5 logs below the standardized baseline; 2) RQ-PCR negativity was confirmed on the next RQ-PCR sample (usually 3 months later); and 3) the date of confirmed CMR was the date of the first of two negative results with sensitivity >4.5 logs.
|
24 months, 36 months, 48 months
|
Progression Free Survival (PFS)
Lasso di tempo: 48 months
|
PFS was defined as the time from the date of randomization to the date of the earliest documented progression-defining event as follows: transformation to blast crisis or accelerated phase disease, or death from any cause.
|
48 months
|
Event-free Survival
Lasso di tempo: 48 months
|
Event-free survival was defined as the time from the date of randomization to the date of first occurrence of any of the following events on study treatment: loss of complete hematological response, confirmed loss of complete cytogenetic response (CCyR), confirmed loss of major molecular response (MMR), death from any cause during treatment, progression to the accelerated phase or blast crisis of chronic myelogenous leukemia (CML) per European Leukemia Network (ELN) criteria, whichever was earliest.
|
48 months
|
Overall Survival
Lasso di tempo: 48 months
|
Overall survival was defined as the time from the date of randomization to the date of death due to any cause at any time during the study, including the follow-up period after discontinuation of treatment.
|
48 months
|
Collaboratori e investigatori
Sponsor
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Neoplasie per tipo istologico
- Neoplasie
- Malattie del midollo osseo
- Malattie ematologiche
- Malattie mieloproliferative
- Leucemia
- Leucemia, mieloide
- Leucemia, Mielogena, Cronica, BCR-ABL Positivo
- Meccanismi molecolari dell'azione farmacologica
- Inibitori enzimatici
- Agenti antineoplastici
- Inibitori della chinasi proteica
- Imatinib mesilato
Altri numeri di identificazione dello studio
- CAMN107A2405
- 2009-012616-40 (Numero EudraCT)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Nilotinib
-
Novartis PharmaceuticalsTerminatoIpertensione arteriosa polmonareSvizzera, Stati Uniti, Germania, Singapore, Corea, Repubblica di, Canada
-
Niguarda HospitalCompletatoLeucemia, mieloide, fase cronicaItalia
-
Georgetown UniversitySconosciutoMorbo di Parkinson | Malattia Di Parkinson Con DemenzaStati Uniti
-
KeifeRx, LLCWorldwide Clinical Trials; Life Molecular Imaging GmbH; Sun Pharmaceuticals Industries...Non ancora reclutamento
-
Shenzhen Second People's HospitalDongguan People's Hospital; Zhongshan People's Hospital, Guangdong, China; The... e altri collaboratoriReclutamentoLeucemia mieloide cronica, fase cronica | NilotinibCina
-
Andrew J. Wagner, MD, PhDMassachusetts General Hospital; Novartis; Brigham and Women's HospitalAttivo, non reclutanteTumore a cellule giganti tenosinoviale | Sinovite villonodulare pigmentata | Tumore a cellule giganti di tipo diffusoStati Uniti
-
Novartis PharmaceuticalsNon più disponibileSindrome ipereosinofila (HES)
-
Novartis PharmaceuticalsNon più disponibile
-
Novartis PharmaceuticalsCompletato